These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 16285354)

  • 21. Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study.
    Purdy J; Jouve S; Yan JL; Balter I; Dartois N; Cooper CA; Korth-Bradley J
    Clin Ther; 2012 Feb; 34(2):496-507.e1. PubMed ID: 22249106
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline.
    Falagas ME; Karageorgopoulos DE; Dimopoulos G
    Curr Drug Metab; 2009 Jan; 10(1):13-21. PubMed ID: 19149509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tigecycline: a novel glycylcycline.
    Rubinstein E; Vaughan D
    Drugs; 2005; 65(10):1317-36. PubMed ID: 15977966
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms.
    Garrison MW; Neumiller JJ; Setter SM
    Clin Ther; 2005 Jan; 27(1):12-22. PubMed ID: 15763603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of tigecycline on normal oropharyngeal and intestinal microflora.
    Nord CE; Sillerström E; Wahlund E
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3375-80. PubMed ID: 17005820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antimicrobial activity and pharmacokinetics/pharmacodynamics of the novel glycylcycline, tigecycline.
    Peterson LR
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):163-4. PubMed ID: 16105559
    [No Abstract]   [Full Text] [Related]  

  • 27. Lack of effect of extracorporeal membrane oxygenation on tigecycline pharmacokinetics.
    Veinstein A; Debouverie O; Grégoire N; Goudet V; Adier C; Robert R; Couet W
    J Antimicrob Chemother; 2012 Apr; 67(4):1047-8. PubMed ID: 22207598
    [No Abstract]   [Full Text] [Related]  

  • 28. [Tigecycline: antimicrobial action, chemotherapeutic efficacy and adverse reactions].
    Nikitin AV
    Antibiot Khimioter; 2009; 54(1-2):63-6. PubMed ID: 19499721
    [No Abstract]   [Full Text] [Related]  

  • 29. Tigecycline: a critical update.
    Shakil S; Akram M; Khan AU
    J Chemother; 2008 Aug; 20(4):411-9. PubMed ID: 18676218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tigecycline for the treatment of patients with community-acquired pneumonia requiring hospitalization.
    Falagas ME; Metaxas EI
    Expert Rev Anti Infect Ther; 2009 Oct; 7(8):913-23. PubMed ID: 19803699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations.
    Sun HK; Ong CT; Umer A; Harper D; Troy S; Nightingale CH; Nicolau DP
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1629-32. PubMed ID: 15793157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clevidipine: a review of its use in the management of acute hypertension.
    Deeks ED; Keating GM; Keam SJ
    Am J Cardiovasc Drugs; 2009; 9(2):117-34. PubMed ID: 19331440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections.
    Falagas ME; Vardakas KZ; Tsiveriotis KP; Triarides NA; Tansarli GS
    Int J Antimicrob Agents; 2014 Jul; 44(1):1-7. PubMed ID: 24602499
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections.
    Van Wart SA; Owen JS; Ludwig EA; Meagher AK; Korth-Bradley JM; Cirincione BB
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3701-7. PubMed ID: 16940069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tigecycline: clinical evidence and formulary positioning.
    Nathwani D
    Int J Antimicrob Agents; 2005 Mar; 25(3):185-92. PubMed ID: 15737510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tigecycline pharmacokinetic/pharmacodynamic update.
    MacGowan AP
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i11-6. PubMed ID: 18684702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model.
    Koomanachai P; Kim A; Nicolau DP
    J Antimicrob Chemother; 2009 May; 63(5):982-7. PubMed ID: 19279050
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics-pharmacodynamics of tigecycline in patients with community-acquired pneumonia.
    Rubino CM; Bhavnani SM; Forrest A; Dukart G; Dartois N; Cooper A; Korth-Bradley J; Ambrose PG
    Antimicrob Agents Chemother; 2012 Jan; 56(1):130-6. PubMed ID: 21968360
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungs.
    Crandon JL; Kim A; Nicolau DP
    J Antimicrob Chemother; 2009 Oct; 64(4):837-9. PubMed ID: 19696049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Tigecycline, the first of a new class of antibiotics: the glycylcyclines].
    Bosó-Ribelles V; Roma-Sánchez E; Salavert-Lletí M; Hernández-Martí V; Poveda-Andrés JL
    Rev Esp Quimioter; 2007 Mar; 20(1):19-35. PubMed ID: 17530033
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.